The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications

The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications

Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second direct myosin activator, has achieved encouraging results in preclinical and clinical studies, thus implicating its potential applicability in the treatment of heart failure with reduced ejection fract...

Full description

Bibliographic Details
Main Authors: Arnold Péter Ráduly, Fruzsina Sárkány, Máté Balázs Kovács, Brigitta Bernát, Béla Juhász, Zoltán Szilvássy, Róbert Porszász, Balázs Horváth, Norbert Szentandrássy, Péter Nánási, Zoltán Csanádi, István Édes, Attila Tóth, Zoltán Papp, Dániel Priksz, Attila Borbély
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:International Journal of Molecular Sciences
Subjects:
heart failure with reduced ejection fraction
myosin activators
danicamtiv
positive inotropy
strain
diastolic dysfunction
Online Access:https://www.mdpi.com/1422-0067/24/1/446

Internet

https://www.mdpi.com/1422-0067/24/1/446

Similar Items